<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935321</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT No. 2016-001227-31</org_study_id>
    <nct_id>NCT03935321</nct_id>
  </id_info>
  <brief_title>NISCI - Nogo Inhibition in Spinal Cord Injury</brief_title>
  <acronym>NISCI</acronym>
  <official_title>Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EMSCI.org</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Secretariat for Education Research and Innovation, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Horizon 2020 - European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation Wings For Life</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Paraplegic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University Hospital Spinal Cord Injury Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the NISCI trial is to test if an antibody therapy can improve movement and
      quality of life of tetraplegic patients. A previous trial showed this treatment is safe and
      well accepted. This is a placebo controlled, randomized, double blind, multicenter,
      multinational study to assess the safety, tolerability, feasibility and preliminary efficacy
      of early (within 4-28 days post injury) initiation of treatment with repeated bolus
      injections of NG-101 in cervical acute SCI patients. The study has 3 phases:
      screening/baseline Phase, treatment phase, and a follow-up phase.

      The study design will allow simultaneous enrolment of patients with complete or incomplete
      SCI. Enrolment and stratification of the patients is based and individualized prediction of
      upper limb outcomes.

      For further information please visit NISCI website: https://nisci-2020.eu
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of upper extremity motor scores (UEMS) according to the International Standards for the Neurological Classification of Spinal Cord Injury</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of effect on motor and sensory function according to the ISNCSCI protocol</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on autonomic dysfunction measured by bladder diary</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on quality life of patients with neuro-urological disorders as measured by Qualiveen questionnaire</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on autonomic dysfunction as measured by bladder function assessment</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on functioning, evaluated by the Spinal Cord Independence Measure (SCIM-III)</measure>
    <time_frame>Change from baseline at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on hand/upper limb function as assessed by the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)</measure>
    <time_frame>Change from baseline at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on the Walking Index for Spinal Cord Injury (WISCI</measure>
    <time_frame>Change from baseline at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on 10 meter walk test (10mWT)</measure>
    <time_frame>Change from baseline at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effect on 6-minute walking test (6MWT)</measure>
    <time_frame>Change from baseline at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effects on nerve conducting velocity</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effects on somatosensory evoked potentials</measure>
    <time_frame>Change from screening at day 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of concentration NG-101 in serum (pharmacokinetics)</measure>
    <time_frame>Change from day 0 at day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of concentration NG-101 in CSF (pharmacokinetics)</measure>
    <time_frame>Change from day 0 at day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Spinal Cord Injury, Acute</condition>
  <arm_group>
    <arm_group_label>Patients with acute cervical spinal cord injury: NG-101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with acute cervical spinal cord injury: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NG-101</intervention_name>
    <description>6 intrathecal bolus injections, each of 45mg</description>
    <arm_group_label>Patients with acute cervical spinal cord injury: NG-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>6 intrathecal bolus injections, each of 45mg</description>
    <arm_group_label>Patients with acute cervical spinal cord injury: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute cervical spinal cord injury (SCI) (Neurological level of injury C1-C8 with
             confirmed classification of ASIA impairment scale (AIS) A-D at screening and predicted
             upper extremities motor score (UEMS) recovery of less than 41/50 (according to the URP
             prediction model)

          -  4-28 days post-injury

          -  No required mechanical ventilation or patients that not completely depend on
             mechanical ventilation

          -  Hemodynamically and clinical stable patient according to the acute SCI condition at
             baseline

          -  Written informed consent

          -  Cooperation and willingness to complete all aspects of the study

          -  Ability of subject to understand character and individual consequences of the study

        Exclusion Criteria:

          -  Complete anatomical transection confirmed by magnetic resonance imaging (MRI)

          -  Trauma caused by ballistic or other injury that directly penetrates the spinal cord
             including gunshot and knife wounds

          -  Major brachial or lumbar plexus damage/trauma

          -  Significant head trauma or other injury that was, in the opinion of the investigator,
             sufficient to interfere with the assessment of the spinal cord function

          -  Other significant pre-existing or current severe systemic disease such as lung, liver
             (exception: history of uncomplicated Hepatitis A), gastorintestinal, cardiac,
             immunodeficiency (including anamnestic known HIV) or kidney disease; or active
             malignancy

          -  History of or an acute episode of Guillain-Barre syndrome

          -  History of recent (6 months) meningitis or meningoencephalitis

          -  History of refractory epilepsy

          -  History of or current autoimmune disease

          -  Patients with uncontrolled bleeding diathesis and/or who require concomitant treatment
             with coumarin anticoagulant

          -  Presence of any unstable medical or psychiatric condition

          -  Drug dependence any time during the 6 month's preceding study entry

          -  Pregnant or nursing women

          -  History of a life-threatening allergic or immune mediated reaction

          -  Patients with the presence of infection around the location where the spinal needle
             insertions are planned for applying the intrathecal injections

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulations

          -  Patients who are unconscious

          -  History of hypersensitivity to the investigational medicinal product or to any drug
             with similar chemical structure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Curt, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universität Zürich / University Hospital Balgrist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Weidner, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Prusse, SC</last_name>
    <phone>+41 44 386 59 70</phone>
    <email>nisci@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iris Krüsi, SN</last_name>
    <phone>+41 44 510 72 22</phone>
    <email>nisci@balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spinal Cord Unit, University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiri Kriz, Dr.</last_name>
      <email>nisci@fnmotol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Querschnittgelähmte, Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Mayer, SC</last_name>
      <email>nisci@klinikum-bayreuth.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behandlungszentrum für Rückenmarkverletzte, Unfallkrankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Liebscher, Dr. med.</last_name>
      <email>rmv-studien@ukb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abteilung für Rückenmarkverletzte, BG Universitätsklinikum Bergmannsheil gGmbH</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dennis Grasmücke, Dr. med.</last_name>
      <email>nisci@bergmannsheil.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Röhl, Dr. med.</last_name>
      <email>nisci@bergmannstrost.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Paraplegiologie, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heutehaus Laura</last_name>
      <email>nisci.ouk@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Langpape Annette</last_name>
      <email>nisci.ouk@med.uni-heidelberg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zentrum für Tetra- und Paraplegie, Orthopädische Klinik Hessisch Lichtenau gGmbH</name>
      <address>
        <city>Hessisch Lichtenau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hüge, SN</last_name>
      <email>nisci@lichtenau-ev.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Rückenmarksverletzte, Unfallklinik Murnau</name>
      <address>
        <city>Murnau Am Staffelsee</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orpheus Mach</last_name>
      <email>nisci@bgu-murnau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BG Klinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Reumann, Dr.</last_name>
      <email>nisci@bgu-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Neurorehabilitation, Santa Lucia Foundation</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcella Masciullo, Dr. PhD</last_name>
      <email>nisci@hsantalucia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Neurorehabilitation, Fundacio Institut Guttmann</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesus Benito, Dr.</last_name>
      <email>nisci@guttmann.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rehab Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Hug, Dr. med.</last_name>
      <email>nisci@rehab.ch</email>
    </contact>
    <contact_backup>
      <last_name>Carmen Rinaldo, SN</last_name>
      <email>nisci@rehab.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schweizer Paraplegikerzentrum</name>
      <address>
        <city>Nottwil</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Rickenbacher, SC</last_name>
      <email>nisci@paraplegie.ch</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Schliessmann, SC</last_name>
      <email>nisci@paraplegie.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Balgrist</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Prusse</last_name>
      <phone>+41 44 386 59 70</phone>
      <email>nisci@balgrist.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Kucher K, Johns D, Maier D, Abel R, Badke A, Baron H, Thietje R, Casha S, Meindl R, Gomez-Mancilla B, Pfister C, Rupp R, Weidner N, Mir A, Schwab ME, Curt A. First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury. Neurorehabil Neural Repair. 2018 Jun;32(6-7):578-589. doi: 10.1177/1545968318776371. Epub 2018 Jun 5.</citation>
    <PMID>29869587</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tetraplegia</keyword>
  <keyword>Trauma</keyword>
  <keyword>Upper limbs function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

